412 related articles for article (PubMed ID: 25267595)
1. Molecular diagnosis of intrahepatic cholangiocarcinoma.
Haga H; Patel T
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):114-23. PubMed ID: 25267595
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
3. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis.
Rahnemai-Azar AA; Weisbrod A; Dillhoff M; Schmidt C; Pawlik TM
Surg Oncol; 2017 Jun; 26(2):125-137. PubMed ID: 28577718
[TBL] [Abstract][Full Text] [Related]
4. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI; Gores GJ
Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
[TBL] [Abstract][Full Text] [Related]
6. [Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
Goeppert B
Pathologe; 2020 Sep; 41(5):488-494. PubMed ID: 32757029
[TBL] [Abstract][Full Text] [Related]
7. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
[TBL] [Abstract][Full Text] [Related]
8. Pathology of Cholangiocarcinomas.
Guedj N
Curr Oncol; 2022 Dec; 30(1):370-380. PubMed ID: 36661679
[TBL] [Abstract][Full Text] [Related]
9. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
10. Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.
Ochoa-Rios S; Blaschke CRK; Wang M; Peterson KD; DelaCourt A; Grauzam SE; Lewin D; Angel P; Roberts LR; Drake R; Mehta AS
Cancer Res Commun; 2023 Mar; 3(3):383-394. PubMed ID: 36890858
[TBL] [Abstract][Full Text] [Related]
11. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments.
Capuozzo M; Santorsola M; Ferrara F; Cinque C; Farace S; Patrone R; Granata V; Zovi A; Nasti G; Ottaiano A
Mol Cell Probes; 2024 Feb; 73():101951. PubMed ID: 38244704
[TBL] [Abstract][Full Text] [Related]
14. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.
Madoff DC; Abi-Jaoudeh N; Braxton D; Goyal L; Jain D; Odisio BC; Salem R; Schattner M; Sheth R; Li D
Oncologist; 2022 Oct; 27(10):884-891. PubMed ID: 35925597
[TBL] [Abstract][Full Text] [Related]
15. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
[TBL] [Abstract][Full Text] [Related]
16. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
[TBL] [Abstract][Full Text] [Related]
17. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
[TBL] [Abstract][Full Text] [Related]
18. Subcentimetric Incidental Intrahepatic Cholangiocarcinoma in an Explant Liver: Diagnostic Difficulty of a Rare Entity.
Mitra S; Geethanjali G; Rathi S; Behera A; Das A
Int J Surg Pathol; 2018 Dec; 26(8):739-744. PubMed ID: 29742944
[TBL] [Abstract][Full Text] [Related]
19. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
20. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.
;
J Hepatol; 2023 Jul; 79(1):181-208. PubMed ID: 37084797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
